OncoMatch/Clinical Trials/NCT03980002
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
Is NCT03980002 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including FCR and Ibrutinib and BR and Ibrutinib for chronic lymphocytic leukemia.
Treatment: FCR and Ibrutinib · BR and Ibrutinib · Ibrutinib and Thalidomide — This is a prospective multicenter phase 2 study designed with the purpose to evaluate the response rate and safety of treatment with FCR/BR alternating with ibrutinib in treatment-naive patients with chronic lymphocytic leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: combined chemotherapy (CHOP, COP)
Untreated with combined chemotherapy such as CHOP, COP and so on.
Cannot have received: chemotherapy regimens including fludarabine and bendamustine (fludarabine, bendamustine)
Unteated with chemotherapy regimens including fludarabine and bendamustine.
Cannot have received: BTK inhibitor (ibrutinib)
Unteated with Ibrutinib.
Lab requirements
Kidney function
serum creatinine ≤ 1.5 x upper limit of normal (ULN), unrelated to lymphoma
Liver function
AST and ALT ≤ 4.0 x upper limit of normal (ULN), bilirubin ≤ 2.0 x upper limit of normal (ULN)
Inadequate hepatic and renal function defined as: AST and ALT >4.0 x upper limit of normal (ULN), bilirubin >2.0 x upper limit of normal (ULN), Adequate renal function defined by serum creatinine >1.5 x upper limit of normal (ULN),unrelated to lymphoma.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03980002 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages